The first commercial priority for a clinical-stage biotech should be payer and health economics (HEOR) research. This ensures the clinical trial includes endpoints that demonstrate clear value to payers, which is essential for future reimbursement and market access.

An industry veteran reveals that payers, wanting to keep their patient members happy, are highly sensitive to public demand. Pharmaceutical companies can leverage this by generating significant patient and physician interest, which pressures payers into providing more favorable formulary coverage.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

Years before legalization, Mind Medicine Australia launched a therapist training program. This created a ready workforce of over 750 clinicians and, more importantly, turned them into a powerful lobbying group who pressured their own professional bodies for change from within.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.

For life sciences startups, UPMC's model shows that an integrated payer-provider views expensive therapies not just as a line-item cost but as a potential long-term saving. They calculate value based on reducing other system costs like hospital stays, supplemental drugs, or future procedures.

Most drug launch failures stem from three core mistakes: engaging medical affairs too late to educate physicians pre-launch, having a flawed payer and reimbursement strategy, and neglecting to build a robust plan for generating and publishing real-world evidence to support the drug's value proposition.

Don't wait until after FDA approval to think about reimbursement. Smart biotechs engage with payers early and build payer-valued outcomes directly into Phase 2/3 trials. This creates a ready-made value dossier for payers alongside the regulatory submission package.